Navigation Links
Application of Genomatix in silico methods reveals novel cancer associated genes

Genomatix Software GmbH, an in silico systems biology company with headquarter in Munich (Germany), released today that researcher in Dublin, Ireland and Boston, U.S.A. identified novel cancer associated genes, based on strategies and products developed and promoted by Genomatix. Experimental verification by siRNA knock-down and RT-PCR confirmed the in silico results.

"I am delighted that an ever increasing number of scientists proof the validity of our concepts and experience the value of our integrated approach. This excellent work, carried out by researchers at The Conway Institute of the University College, Dublin, The Mater Misericordiae University Hospital in Dublin and The Beth Israel Deaconess Medical Center in Boston demonstrates a straightforward strategy from computer analysis to experimental verification.", says Klaus May, Chief Business Officer at Genomatix. He continues:" Two years ago we introduced our own concepts of an annotation and biology driven microarray analysis pipeline, and were heavily contested in the beginning. Today it is so rewarding to our scientists and developers to see the impact of our own ideas and research to cutting edge science of today."


'"/>

Source:Genomatix Software GmbH


Page: 1

Related biology news :

1. Genomatix, AAAS ink agreement
2. Genomatix Microarray Analysis Pipeline achieves Affymetrix GeneChip compatible?status
3. Genomatix technology facilitates de novo identification of new renal disease associated genes
4. MatBase -- A new transcription factor knowledge base released by Genomatix
5. Ophthalmologists implant five patients with artificial silicon retina microchip
6. Researchers get neurons and silicon talking
7. Nano machine switches between biological and silicon worlds
8. Antioxidant protects against lung damage in silicosis
9. Studies reveal methods viruses use to sidestep immune system
10. New methods of gene delivery using lasers
11. Shift of weather patterns necessitates rethinking of reforestation methods
Post Your Comments:
(Date:11/21/2014)... 2014 Strict laws against distracted driving and ... North American and European automotive sector towards gesture recognition ... systems that are intuitive and able to retrieve information ... New analysis from Frost & Sullivan,s ... Europe and North ...
(Date:11/18/2014)... BOSTON , Nov. 17, 2014   ... HealthCare and EMC collaborate to develop The Partners ... , The Partners Data Lake will allow ... to improve diagnostics, treatment and the lives of ... support research and clinical activities across the Partners ...
(Date:11/12/2014)... 2014 Crossmatch™, a leading provider of biometric ... fingerprint readers have been deployed throughout Montparnasse Pasteleria, ... Mexico . The bakery chain implemented the Crossmatch ... caused by employees clocking in for each other. ... Montparnasse relied on paper timecards and a mechanical time ...
Breaking Biology News(10 mins):Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 3Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 5Montparnasse Pasteleria Achieves Time and Attendance Transparency with Crossmatch U.are.U Fingerprint Readers 2
... the University of Minnesota will help corn and soybean farmers ... change. The project is funded by a five-year, $4.1 ... of Food and Agriculture (NIFA). The aim is to take ... in anticipation of climatic changes such as stronger storms and ...
... (July 6, 2011) A new animal study from Europe ... their newborn,s kidney development. Among the most significant aspects ... too little salt during pregnancy had an adverse effect on ... such disruption can lead to high blood pressure in later ...
... of the hidden dangers that may be lurking in our ... Europe are redevelopments of land that used to belong to ... can leave highly carcinogenic pollutants in the soil. There are ... and treated across Europe, according to EU estimates. Developers ...
Cached Biology News:U of M project will help corn and soybean farmers prepare for climate change 2A mother's salt intake could be key to prenatal kidney development 2A mother's salt intake could be key to prenatal kidney development 3Dealing with pollution James Bond style 2Dealing with pollution James Bond style 3
(Date:11/24/2014)... 24, 2014  Last week, Representatives Gus ... (D-NC) took a bold bipartisan step on behalf ... OPEN Act. Original co-sponsors of the legislation include ... will incentivize drug makers and innovators to "repurpose" ... pediatric cancers, which opens the door to the ...
(Date:11/24/2014)... Continental Clinical Solutions, LLC (Continental) ... trials at its mid-Atlantic late-phase research facility, located ... with the idea of closing patient disparities in ... medical advances," said Continental's CEO, Saleh Stevens ... immortal cell line of Henrietta Lacks, dubious ethical ...
(Date:11/23/2014)... 23, 2014 Apiscent Labs, a ... fine chemical ingredients to the global pharmaceutical and ... its new website, Apiscent.com. , The Apiscent.com homepage ... clean design, easy navigation, rotating images and content ... stand out. , The company’s work ...
(Date:11/22/2014)... November 21, 2014 RURO, Inc., ... provider, has released Limfinity® version 5.1.4. , RURO’s ... of Limfinity® than ever in RURO’s 8 year ... minority framework enhancement. Limfinity® version 5.1.4 is the ... and beyond bug fixes! , Limfinity® 5.1.4 release ...
Breaking Biology Technology:OPEN Act Introduced to Repurpose Drugs for Rare Diseases 2At Continental Clinical Solutions, CEO Saleh Stevens Focuses on Diversity in Clinical Trial Recruitment at Maryland Site 2At Continental Clinical Solutions, CEO Saleh Stevens Focuses on Diversity in Clinical Trial Recruitment at Maryland Site 3RURO Announces Limfinity® version 5.1.4 2
... Champions,Biotechnology, Inc. (OTC Bulletin Board: CSBR), a ... Dr. David,Sidransky, Director of the Head and Neck ... Medicine, to serve as Chairman of the Board,replacing ... since 1991. Dr.,Sidransky was appointed to serve on ...
... to customers in 2006, ALLERCA,s hypoallergenic cats have established a unique ... ... world., WILMINGTON, Calif., Oct. 23 ALLERCA, the company that,developed the ... first kitten deliveries to,eager customers. Since then, the company has delivered dozens ...
... of phase 2 breast cancer data show preferential, ... -- Results from 169 patients treated with adecatumumab ... apparent lack of immunogenicity of the antibody, ... ), a biopharmaceutical company focusing on the development of,novel, proprietary ...
Cached Biology Technology:Dr. David Sidransky Appointed Chairman of Champions Biotechnology, Inc. 2Dr. David Sidransky Appointed Chairman of Champions Biotechnology, Inc. 3Dr. David Sidransky Appointed Chairman of Champions Biotechnology, Inc. 4One Year On, ALLERCA Hypoallergenic Cats Bring 'Sneeze Free' Companionship to Allergy and Asthma Sufferers 2One Year On, ALLERCA Hypoallergenic Cats Bring 'Sneeze Free' Companionship to Allergy and Asthma Sufferers 3Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings 2Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings 3Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings 4Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings 5
For cleavage of 6xHis tags from proteins containing a Factor Xa Protease recognition site Efficient 6xHis tag cleavage (greater than 90%), ...
HIV Reverse Transcriptase provides an excellent target for evaluating antiviral agents or catalyzing error prone synthesis on RNA and DNA templates....
supplied with 10x reaction buffer...
HyPro 100, includes 5 x HyPro20 and HyPro Cabinet. 100 slide capacity. Active vibration system, slide rack and humidity chamber. Ideal for microarray and in situ hybridization....
Biology Products: